← Back to Analyst Consensus 
IOVA Buy
IOVANCE BIOTHERAPEUTICS, INC.
Current Price —
Implied Upside —
Analysts 16
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 4 reiterations from 4 firms
Next Earnings
Nov 5, 2026 (10 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 13, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Oct 8, 2026 | Baird | maintain | Neutral → Neutral | — | 55% |
| Sep 30, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Sep 29, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Sep 17, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Aug 25, 2026 | TD Cowen | maintain | Buy → Buy | — | 54% |
| Aug 20, 2026 | UBS | maintain | Neutral → Neutral | — | 54% |
| Aug 18, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Aug 7, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Aug 7, 2026 | Citizens | maintain | Market Outperform → Market Outperform | — | 47% |
| May 7, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Apr 10, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Mar 5, 2026 | UBS | maintain | Neutral → Neutral | — | 54% |
| Mar 3, 2026 | Citizens | upgrade | Market Perform → Market Outperform | — | 47% |
| Feb 25, 2026 | Barclays | maintain | Overweight → Overweight | $11 | 53% |
| Feb 25, 2026 | Citizens | upgrade | Market Perform → Market Outperform | $5 | 47% |
| Dec 17, 2025 | Barclays | maintain | Overweight → Overweight | $10 | 53% |
| Nov 24, 2025 | Barclays | maintain | Overweight → Overweight | $9 | 53% |
| Nov 6, 2025 | Chardan Capital | maintain | Buy → Buy | $17 | 47% |
| Oct 29, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $9 | 44% |
| Aug 19, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $20 | 44% |
| Aug 8, 2025 | Wells Fargo | maintain | Overweight → Overweight | $14 | 54% |
| Aug 8, 2025 | Chardan Capital | maintain | Buy → Buy | $20 | 47% |
| Jul 23, 2025 | Chardan Capital | maintain | Buy → Buy | $25 | 47% |
| May 16, 2025 | UBS | downgrade | Buy → Neutral | $2 | 54% |
| May 12, 2025 | Goldman Sachs | maintain | Buy → Buy | $8 | 54% |
| May 12, 2025 | Mizuho | maintain | Outperform → Outperform | $10 | 52% |
| May 12, 2025 | Barclays | maintain | Overweight → Overweight | $4 | 53% |
| May 9, 2025 | JMP Securities | downgrade | Market Outperform → Market Perform | $0 | 53% |
| May 9, 2025 | Chardan Capital | maintain | Buy → Buy | $25 | 47% |
| May 9, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $20 | 44% |
| Apr 17, 2025 | Goldman Sachs | maintain | Buy → Buy | $16 | 54% |
| Apr 14, 2025 | Barclays | maintain | Overweight → Overweight | $5 | 53% |
| Mar 3, 2025 | Truist Securities | maintain | Buy → Buy | $15 | 54% |
| Mar 3, 2025 | Goldman Sachs | maintain | Buy → Buy | $19 | 54% |
| Mar 3, 2025 | Chardan Capital | maintain | Buy → Buy | $30 | 47% |
| Feb 28, 2025 | Baird | maintain | Outperform → Outperform | $20 | 55% |
| Feb 28, 2025 | Piper Sandler | maintain | Neutral → Neutral | $6 | 54% |
| Feb 28, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $32 | 44% |
| Jan 31, 2025 | Piper Sandler | maintain | Neutral → Neutral | $7.5 | 54% |
| Nov 6, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $32 | 44% |
| Oct 24, 2024 | UBS | initiate | — → Buy | $17 | 54% |
| Aug 12, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $32 | 44% |
| Jul 29, 2024 | Piper Sandler | downgrade | Overweight → Neutral | $10 | 54% |
| Jun 28, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $32 | 44% |
| Jun 20, 2024 | JMP Securities | maintain | Market Outperform → Market Outperform | $23 | 53% |
| Jun 3, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $32 | 44% |
| May 31, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $32 | 44% |
| May 24, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $32 | 44% |
| May 10, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $32 | 44% |
Price Target Trend
Jun 12, 2026 Latest: $14.4 Oct 25, 2026
EPS Estimates
+1y $-0.20
Lo: $-0.42 Hi: $-0.10
8 analysts ▲1
0y $-0.45
Lo: $-0.50 Hi: $-0.41
8 analysts ▲1
+1q $-0.08
Lo: $-0.12 Hi: $-0.04
8 analysts ▲2
0q $-0.09
Lo: $-0.10 Hi: $-0.07
8 analysts ▲2
Cross-Platform Signals
No cross-platform signals in the last 90 days